Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXAGEN INC.XGN · Entity 935 | Chief Medical Officer | March 01, 2022 | March 02, 2022 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Chief Medical Officer | August 03, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXAGEN INC.
Report date March 01, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,259 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Tax withholding · Disposed 3,241 · Balance 84,259 F1: The shares were withheld from the Reporting Person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted on February 23, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld from the Reporting Person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted on February 23, 2021.
Spero Therapeutics, Inc.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,311 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 162,311 · Balance 162,311 F1: Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2019 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 3, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2036-08-03 | Direct | 324,675 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 324,675 · Balance 324,675 F2: The shares underlying this option vest as to 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2019 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 3, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option vest as to 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 6, 2026 22:49 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock option (right to buy) · Derivative | 324,675 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001807743-26-000007 · ownership.xml · derivative · entry 2 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,675 Underlying: Common Stock · 324,675 shares Expires 2036-08-03 F2 · derivative.exercise_date: The shares underlying this option vest as to 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 22:49 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 162,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001807743-26-000007 · ownership.xml · nonDerivative · entry 1 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,311 F1 · shares: Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2019 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 3, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:41 UTC | EXAGEN INC. XGN · Entity 935 | Tax withholdingCommon Stock | 3,241 | $7.12 | $23,075.92 |
DisclosureSEC source: 0001274737-22-000019 · wf-form4_164625724694463.xml · nonDerivative · entry 1 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,259 F1 · shares: The shares were withheld from the Reporting Person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted on February 23, 2021. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:23 UTC | EXAGEN INC. XGN · Entity 935 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001274737-22-000011 · wf-form4_164435534136243.xml · nonDerivative · entry 1 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 F1 · shares: Represents 50,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 4, 2022, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control. F2 · balance_after: Represents 50,000 shares of restricted stock units granted on February 4, 2022 and 37,500 shares of restricted stock units granted on February 23, 2021. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:05 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 12,500 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001274737-21-000009 · wf-form4_161429069393025.xml · derivative · entry 2 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-02-22 F3 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on February 23, 2022, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:05 UTC | EXAGEN INC. XGN · Entity 935 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001274737-21-000009 · wf-form4_161429069393025.xml · nonDerivative · entry 1 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of March 1, 2020, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control. F2 · balance_after: Represents 37,500 shares of restricted stock units. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 23:17 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $13.44 | $0.00 |
DisclosureSEC source: 0001209191-20-021345 · doc4.xml · derivative · entry 1 Zack Debra · CIK 0001807743 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-23 F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on March 24, 2021, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.